Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Development of a Cell Free DNA Assay as a Biomarker for Predicting Early Non-response to Therapy in Metastatic Cancer

NCT03892096 is registered in ClinicalTrials.gov with Cadex Genomics as lead sponsor.

NCT NCT03892096
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03892096 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Development of a Cell Free DNA Assay as a Biomarker for Predicting Early Non-response to Therapy in Metastatic Cancer
Lead sponsor
Cadex Genomics
Phase
Observational
Overall status
Completed
Start date
March 1, 2019
Completion date
February 6, 2024
Enrollment
130 (actual)
Sites
12

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic breast cancer, metastatic colorectal cancer, metastatic non-small cell lung carcinoma